Previous 10 | Next 10 |
– Liquidity position at $1.1 billion as of March 31, 2021 to support continued pipeline progress Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2021. "Over the q...
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its first quarter 2021 financial results and provide a corporate update on Wednesday, May 5, 2021, after the close of the U.S. financial markets. The Company will host a question and answer session via conference call and live ...
Cassava a buy on strength of simufilam dataB. Riley has initiated shares of Cassava Sciences (SAVA) with a buy rating and a $78 price target.Given its most recent close, that represents upside of ~46%.Analyst Mayank Mamtani writes that the strength of the company Alzheimer's candidate simufil...
Additional data from the phase 2b ADVISE trial showed that Arena Pharmaceuticals' (ARNA) etrasimod for atopic dermatitis demonstrated significant improvements in patient-reported outcomes.Etrasimod demonstrated statistical significance in the percentage change in weekly peak pruritis, Dermato...
- Etrasimod 2 mg treatment group achieved statistical significance in the percentage change in weekly peak pruritis (PP-NRS), in the change in Dermatology Life Quality Index (DLQI), and in the change in Patient-Oriented Eczema Measure (POEM) - Etrasimod 2 mg was generally well...
- Company highlights dedication to patients, employees, the community, the environment, and shareholders through initiatives focused on responsibility and sustainability, diversity and inclusion, and patient commitment Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today ann...
-Data presentation to be released online at 10:00 AM ET on Friday, April 23, 2021 -Live Q&A session with presenter to be held on Saturday, April 24, 2021 at 3:00 PM ET Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b ADVI...
Halvorsen's 13F portfolio value increased from $27.68B to $36.37B. The number of positions increased from 86 to 96. Viking Global added UnitedHealth, AbCellera Biologics, Walt Disney, and Palo Alto Networks while dropping Analog Devices, CME Group, Comcast, and Exact Sciences. The...
Connect Biopharma has filed proposed terms for its U.S. IPO. The firm is developing antibody-based treatments for inflammatory diseases. While the IPO isn't cheap, CNTB has seen promising Phase 2 trial efficacy results and the IPO is worth a close look for life science investors. ...
What do drugs for weight loss, pulmonary hypertension, and irritable bowel syndrome all have in common? Not much -- except they are all offerings in which Arena Pharmaceuticals (NASDAQ: ARNA) has come close to the finish line over the past two decades, only to come up short. IMA...
News, Short Squeeze, Breakout and More Instantly...
Arena Pharmaceuticals Inc. Company Name:
ARNA Stock Symbol:
NASDAQ Market:
Arena Pharmaceuticals Inc. Website:
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded at a new 52-week high today of $99.95. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares. Arena Pharmaceuticals is a biotechnology company targeting G-protein-couple...
Arena Pharmaceuticals Inc. (NASDAQ:ARNA) traded today at a new 52-week high of $98.57. So far today approximately 748,000 shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Arena Pharmaceuticals Inc. has traded in a range of $45...